Exelixis (NASDAQ: EXEL)
Exelixis Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Exelixis Company Info
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
News & Analysis
2 Stocks Under $30 to Buy and Hold
You don't need to be a millionaire to get started. Investing on a budget can work, too.
Investing in Biotech ETFs
Here are the five best biotech ETFs to invest in right now.
Is Exelixis Stock a Buy Now?
There is one key reason to consider the stock.
2 Top Biotech Stocks Defying the Bear Market
The best may be yet to come for these companies.
The Top Healthcare Stocks to Buy With $100
Both stocks have outperformed the broader market in the last 12 months.
The Smartest Stocks to Buy With $20 Right Now and Hold Forever
These companies can take investors on a lucrative ride, and all for the price of a few lattes.
2 Under-the-Radar Biotech Stocks to Buy in 2023
Companies that don't make a lot of noise can still make you a lot of money.
2 Incredible Stocks to Buy With Less Than $25
Nothing beats a great investment for the price of just a few cups of coffee.
Valuation
Earnings Transcripts
Exelixis (EXEL) Q4 2023 Earnings Call Transcript
EXEL earnings call for the period ending December 31, 2023.
Exelixis (EXEL) Q3 2023 Earnings Call Transcript
EXEL earnings call for the period ending September 30, 2023.
Exelixis (EXEL) Q2 2023 Earnings Call Transcript
EXEL earnings call for the period ending June 30, 2023.
Exelixis (EXEL) Q1 2023 Earnings Call Transcript
EXEL earnings call for the period ending March 31, 2023.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.